Pharmaceutical
-
How Big Is the Right Size For a Clinical Trial?
Read the rest of this entry »When a drug company embarks on a clinical trial, one of the risks it runs is the nonadherence of participants to the rules. In simplest terms, that means if a patient is to take a pill in the morning and another at night, deviating from the schedule is nonadherence. If too many participants deviate, the trial could fail.
An article in Applied Clinical Trials discusses the statistical implications of nonadherence ...
-
Orphan Drugs Forecast to Be 20% Of Sales
Read the rest of this entry »
The orphan drug market is predicted to top $240 billion in the next five years and account for 20% of all prescription drug sales worldwide.
From a market once so small that Congress had to incentivize the development of drugs to treat rare illnesses, EvaluatePharma's 2019 Orphan Drug Report predicts the sector will see a 12.3% CAGR between now and 2024. That's about double the rate of non-orphan prescription ...
-
Hiring the Best Is No Longer a Given For Life Sciences
Read the rest of this entry »
It wasn't that long ago that life sciences companies were considered employers of choice, "offering attractive opportunities and benefits, challenging and rewarding work, and long-term (if not lifetime) employment stability."
Many still are, but the landscape has changed. Today, says an article on PharmaExec, "The power to attract and retain the best in the labor market is no longer a given for life sciences employers."
Referring the changes ...
-
Outsourced Pharma Services Could Top $54 Billion
Read the rest of this entry »
The market for global healthcare contract research is growing at a rate approaching 7% a year, and could top $54.7 billion by 2025.
A study from Grand View Research says the growth is the result of increasing drug development costs. Expiring patents, the increasing number of partnerships and rising R&D costs are putting pressure on drug makers. At the same time, the regulatory process in many countries for drug ...
-
2018 Was a Record Year for VC Activity
Read the rest of this entry »
When talking about venture capitalists, California and its Silicon Valley may be the first place to come to mind. In 2018 the state accounted for well over half the $130.9 billion invested. Massachusetts and New York were second and third.
Last year was a record-breaker for VC investment. The Pitchbook declared, "2018 ended up being a banner year for the VC industry with $130.9 billion invested across 8 ...
-
Clinical Trials Suffering From Lack of Skilled Investigators
Read the rest of this entry »The management of clinical drug trials has never been more complex. Changes in trial protocols and development practices are making it increasingly difficult to meet patient enrollment goals. Meanwhile, finding investigators with the experience to work in these trials where drugs are tested on specific genetic mutations, rather than diseases, is harder than ever.
An article in Applied Clinical Trials details the challenges of engaging principal investigators. The article cites ...
-
Consumers Want Amazon to Sell Drugs
Read the rest of this entry »Amazon is the place to shop for everything from electronics to clothing to auto parts and even groceries. And most Amazon shoppers pay $119 a year to get 2-day shipping, Prime video, free photo storage and access to exclusive deals and more.
But what you can't get on Amazon are drugs.
That's likely to change soon, and when it does the giant retailer will have a ready market. An Investing ...
-
Novartis Is Fast Becoming a Data Science Company
Read the rest of this entry »
A year ago, the leader of one the largest pharmaceutical firms in the world said it was transforming itself into a medicines and data science company.
Ever since, Novartis has been hiring data scientists from outside the industry to mine what CEO Vas Narasimhan described as a "goldmine" of data from thousands of studies and trials. In an interview earlier this month, PharmExec discussed this transformation and how the new ...
-
4 Issues Holding AI Back In Life Sciences
Read the rest of this entry »
There's hardly an industry that artificial intelligence hasn't touched. In one form or another -- machine learning, chatbots and predictive analytics, for example -- AI is rapidly becoming a part of all technologies. The life sciences are no exception, though many professionals believe the industry is lagging in its adoption of AI.
Last summer's survey by The Pistoia Alliance found 42% of life sciences professionals doubting that AI has yet proven its ...
-
Biotech and Pharma: Outlook Is Overall Positive
Read the rest of this entry »For the biotech and pharmaceutical industries, 2018 has proven to be a mixed bag, but with more overall positives than negatives.
In an article reviewing the year so far, and looking ahead to 2019, Peter Young president and managing director of the life science and chemicals investment banking firm Young & Partners, says drug approvals and development escalated and the emergence of new approaches in immuno-oncology, CRISPR, personalized medicine, and ...
